Medicare’s second negotiation round did more than lower one blockbuster drug. It reset the price of 15 medicines at once, with cuts running from 38 percent at the low end to 85 percent at the high end, all effective in 2027. The drugs span the conditions that define later life, including diabetes, cancer, asthma, chronic obstructive pulmonary disease, and heart failure. Taken together, the reductions are projected to save the Medicare program about $12 billion a year, and the size of the individual cuts means the shelf price behind some of the most common prescriptions is about to change sharply.
The 15 drugs and the size of the cuts
The list emerged from the Medicare Drug Price Negotiation Program, which targets high-spending medications that lack generic or biosimilar competition. Because the qualifying drugs are the ones Medicare spends the most on, the affected treatments read like a catalog of chronic-disease management: semaglutide products for diabetes and weight-related conditions, inhaled therapies for respiratory disease, blood thinners, and cancer medicines among them.
The headline range is wide because the drugs started from very different prices. According to the reductions CMS unveiled, the negotiated cuts fall between 38 percent and 85 percent depending on the drug, and the agency put the aggregate reduction at roughly 44 percent across the group. The single most visible example is semaglutide, sold as Ozempic, whose monthly price drops from a $959 list figure to a negotiated $274. Other drugs on the list carry deeper percentage cuts, which is how the range reaches 85 percent at the top.
The selection rules explain why these particular drugs qualified. The negotiation program can target only brand-name medicines that face no generic or biosimilar competition and that have been on the market for at least seven years for conventional drugs or eleven years for biologics, drawn from the products Medicare spends the most on. This is the program’s second round; a first group of ten drugs saw negotiated prices take effect in January 2026, and the fifteen-drug list for 2027 is the next tranche. Because each round adds drugs rather than replacing the last, the number of medicines carrying a negotiated Medicare price grows with every cycle.
Free retirement updates: A quiet rule change can shrink a Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and explains what to do. Get it free.
What the savings mean for a beneficiary’s budget
The program’s dollars split into two streams, and only one of them lands directly in a beneficiary’s pocket. The larger figure, roughly $12 billion a year, is what Medicare itself expects to save on drug spending. The second figure is the out-of-pocket relief for enrollees, estimated at about $685 million once the prices take hold. Both are meaningful, but they answer different questions, and a retiree should read the smaller number as the one that reaches personal cost sharing.
The reason a lower negotiated price helps at the counter is structural. Part D cost sharing is calculated off the price Medicare recognizes for a drug, so cutting that price shrinks the deductible and coinsurance amounts a patient runs through. Layered on top is the redesigned Part D benefit, which now caps annual out-of-pocket drug costs, meaning the negotiated cuts and the spending cap work in the same direction for people with high prescription bills.
Reach matters here because these are not niche drugs. Federal figures tied to the announcement indicate about 5.3 million Medicare beneficiaries use the 15 medicines, which accounted for tens of billions of dollars in Part D spending in a single recent year. A cut concentrated on drugs that millions already take is what turns a policy percentage into a change households can feel.
The prices are not optional for the manufacturers. A drugmaker that declines to offer the negotiated maximum fair price to Medicare faces a steep excise tax or must pull the product from Medicare and Medicaid entirely, which is why the published figures function as real ceilings rather than opening offers. That enforcement is what lets a beneficiary treat the 2027 number as the price the program will actually recognize at the pharmacy, subject to the individual plan’s tier rules.
Why the fine print still governs the counter price
A negotiated price sets the ceiling Medicare pays, not a fixed copay, and that distinction decides how much of the cut a patient actually sees. Each Part D plan still assigns the drug to a formulary tier and applies its own cost-sharing rules, so two enrollees on the same medicine can owe different amounts. The 38-to-85-percent range describes the price Medicare recognizes; the checkout figure depends on plan design.
Timing is the other qualifier. The prices become effective January 1, 2027, and do not apply to fills in the remainder of 2026, so a beneficiary counting on the lower cost is waiting on the new plan year. That gap makes the 2027 plan-comparison season the moment to confirm how a chosen plan treats each of these drugs.
The longer arc, tracked by analysts at the health-policy organization KFF, is that this is the second group of drugs to go through negotiation, with more rounds scheduled in the years ahead. The 15-drug list is a snapshot of a program built to keep expanding, and the 38-to-85-percent cuts are early evidence of how far the recognized price of a widely used medicine can move. For an older household, the practical instruction is narrow but real: check whether a current prescription sits on the 2027 list, then read the plan’s tier for it, because that is where a national percentage becomes a personal number.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
